Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Buy” by Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned an average rating of “Buy” from the eleven analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $156.86.

Several research firms have recently issued reports on ASND. Zacks Investment Research cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Leerink Swann reissued an “outperform” rating and set a $152.00 target price (up from $140.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, December 3rd. Wedbush reissued a “buy” rating and set a $186.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, November 19th. Morgan Stanley boosted their target price on Ascendis Pharma A/S from $134.00 to $140.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Finally, ValuEngine cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd.

Shares of ASND traded down $0.43 during mid-day trading on Friday, hitting $139.14. 1,550 shares of the company’s stock traded hands, compared to its average volume of 227,106. The company has a quick ratio of 15.75, a current ratio of 15.74 and a debt-to-equity ratio of 0.05. Ascendis Pharma A/S has a 1 year low of $66.11 and a 1 year high of $142.94. The firm has a market capitalization of $5.85 billion, a P/E ratio of -37.42 and a beta of 0.67. The business’s 50-day moving average price is $125.66 and its 200-day moving average price is $113.44.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Monday, November 18th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.37) by $0.78. Ascendis Pharma A/S had a negative return on equity of 29.04% and a negative net margin of 789.80%. The firm had revenue of $2.49 million for the quarter, compared to analysts’ expectations of $1.88 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post -4.67 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in shares of Ascendis Pharma A/S by 53.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 7,178,036 shares of the biotechnology company’s stock worth $826,551,000 after acquiring an additional 2,509,034 shares in the last quarter. Invesco Ltd. boosted its stake in Ascendis Pharma A/S by 1,024.8% during the second quarter. Invesco Ltd. now owns 1,014,346 shares of the biotechnology company’s stock worth $116,802,000 after acquiring an additional 924,169 shares in the last quarter. Camber Capital Management LP boosted its stake in Ascendis Pharma A/S by 51.2% during the second quarter. Camber Capital Management LP now owns 650,000 shares of the biotechnology company’s stock worth $74,848,000 after acquiring an additional 220,000 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Ascendis Pharma A/S by 102.5% during the second quarter. Renaissance Technologies LLC now owns 179,799 shares of the biotechnology company’s stock worth $20,704,000 after acquiring an additional 91,000 shares in the last quarter. Finally, Putnam Investments LLC grew its holdings in Ascendis Pharma A/S by 48.1% in the second quarter. Putnam Investments LLC now owns 248,716 shares of the biotechnology company’s stock worth $28,640,000 after purchasing an additional 80,805 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Story: What is the S&P/ASX 200 Index?

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.